Neoadjuvant Radiotherapy with Camrelizumab as a Chemotherapy-Sparing Strategy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: Results from a Phase II Trial (ESOCORT-NIRT) - Summary - MDSpire
Advertisement
Neoadjuvant Radiotherapy with Camrelizumab as a Chemotherapy-Sparing Strategy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: Results from a Phase II Trial (ESOCORT-NIRT)
To evaluate the safety and efficacy of neoadjuvant camrelizumab plus concurrent radiotherapy as a chemotherapy-sparing approach in patients with locally advanced esophageal squamous cell carcinoma, focusing on primary endpoints of major pathological response and safety.
Key Findings:
High rates of major pathological response (MPR) and R0 resection were achieved (specific percentages to be included).
Very low rates of high-grade toxicity (specific percentages to be included) were observed.
Postoperative complications were generally mild.
Interpretation:
The study suggests that neoadjuvant camrelizumab plus radiotherapy can be an effective alternative to traditional chemotherapy-based regimens, particularly for patients unable to tolerate chemotherapy, highlighting its potential role in clinical practice.
Limitations:
Small sample size of 25 patients limits generalizability.
Single-arm design may introduce bias, particularly in patient selection.
Conclusion:
Neoadjuvant camrelizumab combined with radiotherapy shows promise as a chemotherapy-sparing strategy for locally advanced ESCC, warranting further investigation in larger trials.
